Merck & Co Inc

NYSE:MRK   3:59:57 PM EDT
76.95
-1.38 (-1.76%)
4:40:59 PM EDT: $76.91 -0.04 (-0.05%)
Products

Merck Says FDA Approved Keytruda-Lenvima Combination For Patients With Certain Types Of Advanced Endometrial Carcinoma

Published: 07/22/2021 10:53 GMT
Merck & Co Inc (MRK) - FDA Approves Keytruda® (pembrolizumab) Plus Lenvima® (lenvatinib) Combination for Patients With Certain Types of Advanced Endometrial Carcinoma.
Merck & Co Inc - Study Results Demonstrated Statistically Significant Improvements in Overall Survival.
Merck & Co Inc - Approval for Population is Based on Results From Pivotal Phase 3 Keynote-775/study 309 Trial.